Search results for "Nasal polyp"

showing 10 items of 42 documents

Canine fossa puncture in endoscopic sinus surgery: report of two cases

2017

Abstract Introduction Chronic rhinosinusitis with nasal polyposis is a common chronic disease that often affects maxillary sinus. Endoscopic sinus surgery is the most common procedure for treating the majority of maxillary sinus lesions. Objective To demonstrate the role of canine fossa puncture during endoscopic sinus surgery procedure in patients with severe maxillary sinus disease. Methods We present 2 cases where canine fossa puncture has been performed as method to obtain a complete access to the maxillary antrum. Results According our experience, 2 cases on 296 endoscopic sinus surgery (0.6%) where antrostomy and used of angled microdebrider were not sufficient, canine fossa puncture …

medicine.medical_specialtyMaxillary sinusChronic rhinosinusitissinusitisCanine fossa punctureMiddle meatal antrostomyPuncturesMaxillary antrumMaxillary sinusYoung Adult03 medical and health sciencesNasal Polyps0302 clinical medicineMaxillary sinusitisotorhinolaryngologic diseasesmedicineHumansIn patient030223 otorhinolaryngologyAgedMaxillary sinus sinusitis Maxillary sinusitisAlternative methodsAngled microdebriderbusiness.industryOtorhinolaryngology2734 Pathology and Forensic MedicineEndoscopylcsh:Otorhinolaryngologylcsh:RF1-547SurgeryEndoscopic sinus surgerymedicine.anatomical_structureChronic diseaseOtorhinolaryngologyCanine fossaAngled microdebrider; Canine fossa puncture; Maxillary sinusitis; Middle meatal antrostomy; Otorhinolaryngology2734 Pathology and Forensic MedicineChronic DiseaseFemaleTomography X-Ray Computedbusiness030217 neurology & neurosurgery
researchProduct

Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA-ARIA-EPOS-AIRWAYS IC…

2017

Precision medicine (PM) is increasingly recognized as the way forward for optimizing patient care. Introduced in the field of oncology, it is now considered of major interest in other medical domains like allergy and chronic airway diseases, which face an urgent need to improve the level of disease control, enhance patient satisfaction and increase effectiveness of preventive interventions. The combination of personalized care, prediction of treatment success, prevention of disease and patient participation in the elaboration of the treatment plan is expected to substantially improve the therapeutic approach for individuals suffering from chronic disabling conditions. Given the emerging dat…

allergic rhinitis; integrated care pathway; precision medicine; rhinosinusitisAllergyRhinosinusitisDiseaseAllergic rhinitis0302 clinical medicineQUALITY-OF-LIFEMedicineImmunology and Allergy030223 otorhinolaryngologySinusitisNASAL POLYPOSISRhinitisPrecision medicineintegrated care pathway3. Good healthAlgorithmREAL-LIFEIMPACT OUTCOMESARIA and EPOS working groups1107 ImmunologyDISEASESGA(2)LENDisease Progressionallergic rhinitiLife Sciences & BiomedicineENDOSCOPIC SINUS SURGERYAlgorithmsHumanIntegrated care pathwayallergic rhinitis; integrated care pathway; precision medicine; rhinosinusitis; Adult; Algorithms; Chronic Disease; Disease Progression; Humans; Precision Medicine; Rhinitis Allergic; Sinusitis; Young Adult; Immunology and Allergy; ImmunologyAdultmedicine.medical_specialtyprecision medicineImmunologyrhinosinusitiPHENOTYPESVALIDATIONYoung Adult03 medical and health sciencesTherapeutic approachAllergicPatient satisfactionQuality of life (healthcare)HumansSinusitisPatient participationIMMUNOTHERAPYIntensive care medicinerhinosinusitisAsthmaScience & Technologyallergic rhinitis; integrated care pathway; precision medicine; rhinosinusitis; Immunology and Allergy; Immunologyallergic rhinitisbusiness.industrymedicine.diseasePrecision medicineSinusitiRhinitis AllergicSEVERITY030228 respiratory system3121 General medicine internal medicine and other clinical medicineChronic DiseasePhysical therapyASTHMAbusiness
researchProduct

Vascular endothelial growth factor expression in nasal polyps of aspirin-intolerant patients.

2012

Objective To study differences between aspirin-tolerant patients and aspirin-intolerant patients concerning vascular endothelial growth factor (VEGF) expression. Recent publications strongly suggest the involvement of VEGF and its receptors in the pathophysiologic process of nasal polyps. Design We subjected 43 polyp specimens to semiquantitative immunohistochemical analysis. We quantified VEGF and its receptors (Flk, Flt, and neuropilin) in all samples. To gain insight into potential VEGF-mediated cellular responses, we determined proliferative (Ki67) and apoptotic (caspase 3) indices. Patients Polyp samples were obtained from 22 aspirin-intolerant patients and from 21 aspirin-tolerant pat…

AdultMaleVascular Endothelial Growth Factor APathologymedicine.medical_specialtyAdolescentApoptosisStatistics Nonparametricchemistry.chemical_compoundNasal Polypsotorhinolaryngologic diseasesNeuropilinMedicineHumansNasal polypsReceptorAspirinAspirinbusiness.industryCaspase 3General MedicineMiddle Agedmedicine.diseaseImmunohistochemistryPathophysiologyVascular endothelial growth factorVascular endothelial growth factor AKi-67 AntigenReceptors Vascular Endothelial Growth FactorOtorhinolaryngologychemistryImmunohistochemistrySurgeryFemalebusinessmedicine.drugArchives of otolaryngology--headneck surgery
researchProduct

Effects of Omalizumab Treatment in Patients With Recalcitrant Nasal Polyposis and Mild Asthma: A Multicenter Retrospective Study

2021

Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a clinical entity with specific features that impacts significantly on patient quality of life (QoL). CRSwNP is often associated with asthma and is difficult to control and manage despite pharmacological and/or surgical treatment. Omalizumab, a monoclonal anti-IgE antibody, has emerged as a putative therapeutic option. Objective To evaluate the effects of omalizumab on nasal polyp (NP) size and QoL assessed by Sino-Nasal Outcome Test-22 (SNOT-22) in patients with recalcitrant CRSwNP and mild asthma. Methods A multicenter retrospective analysis of patient data from the Community of Valencia (Spain) was performed. Adult patients …

Adultmedicine.medical_specialtyMild asthmaOmalizumabOmalizumabaspirin-exacerbated respiratory diseasechronic rhinosinusitis with nasal polypsImmunoglobulin E03 medical and health sciencesNasal Polyps0302 clinical medicineQuality of lifeSNOT-22Internal medicinemedicineHumansImmunology and AllergyNasal polypsIn patient030223 otorhinolaryngologyRetrospective StudiesRhinitisnasal polypsbiologybusiness.industrytotal nasal endoscopic polyp scoreRetrospective cohort studyGeneral Medicinemedicine.diseaseAsthmaTreatment Outcomequality of lifetissue eosinophilia030228 respiratory systemOtorhinolaryngologyIgE SNOT-22 aspirin-exacerbated respiratory disease chronic rhinosinusitis with nasal polyps mild asthma nasal polyps omalizumab quality of life tissue eosinophilia total nasal endoscopic polyp scoreChronic DiseaseQuality of Lifebiology.proteinomalizumabAspirin exacerbated respiratory diseaseIgEbusinessmild asthmamedicine.drugAmerican Journal of Rhinology & Allergy
researchProduct

Transcriptome Analysis Identifies Doublesex and Mab-3 Related Transcription Factor (DMRT3) in Nasal Polyp Epithelial Cells of Patients Suffering from…

2021

Background: Aspirin-exacerbated respiratory disease (AERD) is a syndrome characterised by chronic rhinosinusitis, nasal polyps, asthma and aspirin intolerance. An imbalance of eicosanoid metabolism with anover-production of cysteinyl leukotrienes (CysLTs) has been associated with AERD. However, the precise mechanisms underlying AERD are unknown. Objective: To establish the transcriptome of the nasal polyp airway epithelial cells derived from AERD patients to discover gene expression patterns in this disease. Methods: Nasal airway epithelial cells were isolated from 12 AERD polyps and 8 AERD non-polyp nasal mucosa samples as controls from the same subjects. Utilising the Illumina HiSeq 2500 …

0301 basic medicineMaleMucous membrane of noseBiochemistryDMRT3TranscriptomeTranscription Factors TFII0302 clinical medicinetranscriptome analysisGene expressionMedicineNasal polypsRNA-SeqEicosanoid metabolismAnti-Inflammatory Agents Non-SteroidalMiddle AgedImmunohistochemistryQR1-502030220 oncology & carcinogenesisImmunohistochemistryFemalemedicine.symptomAdultLeukotrienesAspirin-exacerbated respiratory diseaseInflammationMicrobiologyArticle03 medical and health sciencesImmune systemNasal Polypsotorhinolaryngologic diseasesHumansSinusitisMolecular BiologySkin TestsAspirinbusiness.industryGene Expression Profilingnasal airwayEpithelial Cellsmedicine.diseaseRespiration Disorders030104 developmental biologyImmunologyChronic DiseaseNasal LavageAsthma Aspirin-InducedbusinessTranscriptomeBiomolecules
researchProduct

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

2020

According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managing corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should be considered a primary outcome in the management of severe asthma. New biologics have clearly demonstrated that this effect is possible, with concomitant reduction in the rate of exacerbations and in symptom control. Then, there is no reason for using so frequently oral corticosteroid before having explored al…

ISAR International Severe Asthma RegistrySHARPPediatricsSevere asthmaSA severe asthmaBiologics Oral corticosteroids Real-life Registr Severe asthmaOmalizumabforced expiratory volume in the 1st secondFood &ampGrading of Recommendations Assessmentchronic rhinosinusitis with nasal polyposisFEV1chemistry.chemical_compound0302 clinical medicineQuality of lifeEMAReal WorldEuropean Medicines AgencyBiologics; Oral corticosteroids; Real-life; Registr; Severe asthmaOral corticosteroidsFDA Food & Drug AdministrationImmunology and Allergy030223 otorhinolaryngologySevere Heterogeneous Asthma Research collaborationmusculoskeletal neural and ocular physiologyReal-lifeCRSwNPOCSsBenralizumabDupilumabCRSwNP chronic rhinosinusitis with nasal polyposisGRADESHARP Severe Heterogeneous Asthma Research collaboration Patient-centredSevere Asthma Network in ItalyFDAmedicine.drugPulmonary and Respiratory Medicinelcsh:Immunologic diseases. Allergymedicine.medical_specialtyDrug AdministrationGINA Global Initiative for AsthmaRW Real WorldImmunologymacromolecular substancesRWSettore MED/10 - Malattie Dell'Apparato RespiratorioBiologicsInternational Severe Asthma RegistryISAR03 medical and health sciencesSADisease registrySARP Severe Asthma Research ProgramPatient-centredmedicineAsthmabusiness.industrySettore MED/09 - MEDICINA INTERNASANI Severe Asthma Network in ItalySANIBiological productmedicine.diseaseOCSs Oral CorticoSteroidsGINASARPSevere Asthma Research ProgramFEV1 forced expiratory volume in the 1st second030228 respiratory systemchemistrynervous systemRegistrEMA European Medicines AgencyDevelopment and EvaluationSevere asthma Biologics Oral corticosteroids Real-life Registrbusinesslcsh:RC581-607Global Initiative for AsthmaMepolizumabGRADE Grading of Recommendations Assessment Development and Evaluation
researchProduct

Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry

2020

Abstract Background The clinical and laboratory features of patients enrolled in the Severe Asthma Network in Italy (SANI) registry, a web-based observatory collecting demographic, clinical, functional and inflammatory data of patients with severe asthma were evaluated, with a special emphasis to chronic rhinosinusitis with nasal polyposis (CRSwNP). Methods For each eligible patients the following information has been collected: demographic data, clinical features, asthma control in the previous month according to the GINA (Global INitiative for Asthma) Guidelines and standardized questionnaires, concomitant regular and on demand treatments and inflammatory markers. Results 695 patients wit…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtySevere asthmaDatabases FactualAdministration OralComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioNitric OxideSeverity of Illness IndexComorbiditiesOral corticosteroidAdrenal Cortex HormonesInternal medicineSeverity of illnessOral corticosteroidsmedicinePrevalenceNasal polypsHumansNasal polypsRegistriesSinusitisSinusitisAsthmaAgedRhinitisInternetBronchiectasisbusiness.industryNasal polypSettore MED/09 - MEDICINA INTERNAAtopic dermatitisComorbidities; Nasal polyps; Oral corticosteroids; Severe asthmaMiddle Agedmedicine.diseaseComorbidityAsthmaComorbidities Nasal polyps Oral corticosteroids Severe asthmaItalyConcomitantChronic DiseaseDisease ProgressionFemaleComorbiditiebusiness
researchProduct

Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.

2019

Background An estimated 7% of patients with asthma have chronic rhinosinusitis with nasal polyps (CRSwNP), and more than 80% have at least some radiographic evidence of sinonasal inflammation. Aspirin sensitivity is strongly associated with elevated blood eosinophil levels and increased asthma severity. Intravenous (IV) reslizumab has been shown to improve asthma control in patients with nasal polyps. Objective These post hoc analyses of pooled data from 2 BREATH phase 3 clinical trials, studies 1 and 2 (NCT01287039 and NCT01285323), examined asthma-related outcomes in patients with comorbid, self-reported CRSwNP with and without aspirin sensitivity. Methods Patients aged 12-75 years with e…

AdultMalemedicine.medical_specialtyAdolescentComorbidityPlaceboAntibodies Monoclonal Humanized03 medical and health sciencesYoung Adult0302 clinical medicineNasal PolypsReslizumabMaintenance therapyInternal medicinemedicineImmunology and AllergyHumansNasal polyps030212 general & internal medicineAnti-Asthmatic AgentsPulmonary EosinophiliaSinusitisChildAsthmaAgedRhinitisAspirinbusiness.industryMinimal clinically important differenceAnti-Inflammatory Agents Non-SteroidalEosinophilMiddle Agedmedicine.diseaseAsthmarespiratory tract diseasesEosinophilsmedicine.anatomical_structureTreatment Outcome030228 respiratory systemAsthma Control QuestionnaireChronic DiseaseFemaleSelf Reportbusinessmedicine.drugThe journal of allergy and clinical immunology. In practice
researchProduct

MUC4 overexpression correlates corticoid resistance in chronic rhinosinusitis with nasal polyps

2015

Background: Some patients with chronic rhinosinusitis with nasal polyps (CRSwNP) are resistant to corticoids. Mucin 4 (MUC4) is a membrane anchored protein with a nuclear translocation domain which is modulated by corticoids. Because glucocorticoid receptor (GR) nuclear translocation is key to the anti-inflammatory effect of corticoids, we hypothesized that MUC4 is involved in the effectiveness of these drugs Objective: To analyze the role of MUC4 in corticoid effectiveness in different cohorts of patients with CRSwNP and elucidate the possible mechanisms involved Methods: 73 patients with CRSwNP took oral corticoids for 15 days. Corticoid resistance was evaluated by nasal endoscopy. The ex…

Gene knockdownmedicine.medical_specialtybusiness.industryMucinmedicine.diseaseBlotGlucocorticoid receptorEndocrinologyDownregulation and upregulationInternal medicineImmunologymedicineImmunohistochemistryNasal polypssense organsbusinessDexamethasonemedicine.drug5.1 Airway Pharmacology and Treatment
researchProduct

Olfactory function after microscopic endonasal surgery in patients with nasal polyps.

1997

A controlled prospective study on 31 patients with nasal polyps was performed to evaluate the time course of olfactory function after endonasal surgery. A modified Connecticut Chemosensory Clinical Research Center (CCCRC) olfactory function test was used to measure olfactory threshold, odor identification ability, and odor discrimination ability. The test was performed in all patients 1–3 days before surgery (V1), 7–10 days after surgery (V2), and after 1 (V3), 2 (V4), 3 (V5), and 6 (V6) months. Mean olfactory threshold in the CCCRC butanol test was 4.19 at V1 (= moderate hyposmia). At V2, it decreased to 3.46 (= severe hyposmia), before increasing to 5.16 at V3 and 5.22 at V4 (= mild hypo…

Olfactory systemAdultMalemedicine.medical_specialtyTime Factors03 medical and health sciences0302 clinical medicineNasal PolypsmedicineHumansIn patientNasal polypsProspective Studies030223 otorhinolaryngologyProspective cohort studyPostoperative Carebusiness.industryEndoscopyOlfactory PathwaysMiddle Agedmedicine.diseaseSurgerySmellOtorhinolaryngology030220 oncology & carcinogenesisTime courseFemalebusinessAmerican journal of rhinology
researchProduct